Cingulate Inc. (CING), a clinical-stage biopharmaceutical company developing treatments for anxiety-associated disorders, is gearing up for a regulatory milestone this year for its lead ADHD asset CTx-1301.
CTx-1301 utilizes the company's proprietary Precision Timed Release (PTR) drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. This drug candidate is designed to be the first true, once-daily stimulant medication that treats ADHD over an entire active day, and that offers eight dose strengths so that medical professionals can effectively optimize a patient's medication.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.